Histologically proven stage IIIB or IV non-small cell lung cancer
patients harboring sensitive EGFR mutations and received first-generation EGFR-TKIs who developed acquired drug resistance
patients who can provide pre-treatment (EGFR TKIs) tumor tissues
patients with tumor lesions to be re-biopsy after drug resistance
patients must sign an informed consent indicating that they are aware of the .investigational nature of the study in keeping with the policy of the hospital.
You may not be if
History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix
patients with other systemic diseases
Clareo Health | Acquired Resistant Mechanism of the First-generation EGFR TKIs
